Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
December 02, 2024
03:00 PM - 03:45 PM ET
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 18, 2024
12:00 PM - 01:30 PM ET
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Redefining Treatment at First Relapse in RRMM: Exploring BCMA-Targeted Therapies
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
